The University of Toronto-spin-out which works on molecular diagnostics has landed $10m in a series A round partially funded by Qiagen, a testing technology company.
Xagenic, a Canada-based molecular diagnostics company spun-out from research at the University of Toronto, closed a $10m series A round on Monday from investors including biotechnology company Qiagen N.V.
The round was co-led by venture capital investment partnership CTI Life Sciences Fund and regional government-backed investment unit the Ontario Emerging Technologies Fund.
Xagenic previously raised a $2.2m seed round in October 2010, led by MaRS Innovation, a commercialisation agent for the intellectual property developed by its academic and healthcare…
